Recently, Exelixis declared that the U.S. FDA (Food and Drug Administration) has granted approval for Cabometyx (cabozantinib) tablets for individuals having HCC (hepatocellular carcinoma) and who have been earlier treated with sorafenib. HCC is the main general form of liver cancer and the fastest-mounting cause of cancer-interrelated fatalities in the U.S. Michael M. Morrissey—CEO and President of Exelixis—stated, “This recent clue for Cabometyx is a significant treatment advancement for patients having this aggressive type of liver cancer and community who is in need of novel therapeutic options. This sanction is an imperative milestone as we maintain to explore how Cabometyx might help individuals with the difficult-to-treat type of cancers ahead of renal cell carcinoma.”
The FDA’s sanction of Cabometyx was done on the basis of outcomes obtained from the Phase III pivotal test of Cabometyx for individuals with progressed HCC who seek sorafenib earlier. Cabometyx exhibited a clinically meaningful and statistically significant improvement in OS (overall survival) against placebo. On November 15, 2018, Exelixis’ associate Ipsen obtained certification from the EC (European Commission) for Cabometyx tablets as a mono-therapy for HCC patients who have formerly been treated with sorafenib.
On a similar note, recently, the FDA was in news as it has approved Tdap (tetanus, diphtheria, and acellular pertussis) booster vaccine. The U.S. FDA has enlarged the use of Tdap absorbed vaccine—Adacel—to comprise reiterate vaccinations for tetanus, diphtheria, and pertussis. With the suggestion, Sanofi Pasteur product is the first only Tdap vaccine that is approved for recurring dose in individuals aged from 10–64 Years old—8 Years or more following their first vaccination—in the U.S This vaccine is also at present the only Tdap vaccine obtainable in syringe made lacking natural rubber latex, owing to patient allergy.